Logo

Accelrys Buys Three BlueArc Titan Servers for Data Storage, Consolidation

Mar 22, 2005

NEW YORK, March 22 (GenomeWeb News) - Accelrys has selected BlueArc's Titan SiliconServers as its standard storage platform, the companies said today.

 

Specifically, Accelrys bought three SiliconServers, which equates to more than 40 terabytes of storage, to consolidate data from its operations in San Diego; Cambridge, UK; and Bangalore, India.

 

In a statement, BlueArc said Accelrys will use the servers to "support gene sequence processing, engineering build data, and the associated Oracle databases." Accelrys client PCs are also "backed up directly to Titan, which is capable of handling dozens of streams concurrently," BlueArc said.

Accelrys said Titan will help it "eliminate the capacity and performance limitations that were inherent in its current Network Attached Storage environment."
The company has "a goal of utilizing Titan for 4-5 years, if not longer," Carol Busch, IT manager at Accelrys, said in the statement.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.